News

Lowering cholesterol is a key component in the prevention and management of heart disease. Earlier preclinical “in vitro” studies gave Samaritan reason to believe its proprietary peptide SP-1000

The company also recently announced similar approval from the FDA for a similar trial in the US In the trial, patients will undergo a closing of a small

The patients being enrolled in the trial have disease which has begun to progress following at least two prior therapeutic campaigns, either conventional or experimental. Cell-based studies have

The extra six months of exclusivity was granted after Cephalon met the terms of a written request to provide data from clinical studies examining the effect of Provigil

BG Medicine (BGM) will apply their proprietary, integrated systems approach based on proteomics, metabolomics and computational analyses to describe the molecular effects of selected lipid lowering agents on

The collaboration is focused on the development and commercialization of BCR-ABL inhibitors for the treatment of drug resistant chronic myelogenous leukemia (CML). The new agreement will see SGX

In response to news of the allegation, Schering released a statement which affirmed the company’s belief that Yaz does not infringe on the patent, and that the launch

The 80-patient, multi-center trial will be compared to an historical control group of 80 patients, with survival at day 100 as the primary endpoint. Severe veno-occlusive disease (VOD)

Operating expenses decreased to $10.6 million for the first quarter of 2009 from $12.0 million for the first quarter of 2008, primarily as a result of a strategic